More regular updates and key information, updates and news can be found thorugh our tweets
Latest tweets from @CellCentric
CellCentric’s Finance Director, Thea Stanway at the @BIA_UK’s excellent Women in Biotech meeting, Hinxton, Cambridge. #EmbraceEquity
March is Multiple Myeloma Awareness Month. CellCentric’s oral drug, inobrodib impacts IRF4 and MYC, key drivers of myeloma. Initial clinical data shared at ASH22.
CellCentric’s inobrodib is an oral small molecule drug that inhibits p300/CBP. That impacts key drivers of multiple myeloma, IRF4 and MYC.